Review chapter on T2DM management in pregnancy, covering glycemic monitoring, insulin as the standard treatment, and the limited but emerging data on GLP-1 RAs, tirzepatide, SGLT2 inhibitors, and DPP-4 inhibitors in pregnant women. Emphasizes the absence of adequate safety data for newer agents. Provides an evidence-based framework for managing T2DM in pregnancy where insulin remains standard—informing obstetricians and endocrinologists on when tirzepatide or semaglutide use may constitute inadvertent fetal exposure and the appropriate transition strategy when pregnancy is confirmed.
Wilkie, Gianna